Ionis Pharmaceuticals
IONSNASDAQAntisense oligonucleotide discovery and development platform
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
Filing figures as of June 30, 2026 · text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
IONS filings on EDGAR →Cash & investments
$2.70B
at June 30, 2026 (10-Q)
Quarterly operating burn
$114M
average per quarter, Jan–Jun 2026
Cash runway
~71 months
$2.70B ÷ $114M per quarter
Shares outstanding
166.2M
cover page of the latest filing
Read from IONS's XBRL financial data; latest filing July 29, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Early revenue.
Upcoming catalysts
Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.
Donidalorsen OLE: Donidalorsen in Hereditary angioedema prophylaxis — primary completion
2026-12
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Donidalorsen paediatric: Donidalorsen in Hereditary angioedema, ages 2 to <12 — primary completion
2029-06
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Olezarsen paediatric FCS: Olezarsen in Familial chylomicronemia syndrome — primary completion
2030-08
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Tryngolza | familial chylomicronemia syndrome | Approved | Not disclosed | ▼ |
| Donidalorsen | hereditary angioedema | Phase 3 | Not disclosed | ▼ |
| Olezarsen | severe hypertriglyceridemia | Phase 3 | Not disclosed | ▼ |
Analysis
Comparable companies
Sponsored
Get premium IONS analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you